TNG Transgene SA

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024



TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2024.

The document is available on the Company’s website: , in the “Investors/Financial information” section.

This report comprises the following documents:

  • 2024 half-year financial statements;
  • Half-year management report;
  • Statutory Auditors’ report on the 2024 half-year financial statements;
  • Declaration by the person responsible for this half-year financial report.

Contacts

Media: 
Caroline Tosch 
Responsable Communication Corporate 
+33 3 68 33 27 38 
  
 
Investisseurs : 
Nadège Bartoli 
Chargée relations investisseurs 
+33 3 88 27 91 03 
Lucie Larguier 
Directrice Financière 
+33 3 88 27 91 00 
 

Attachment



EN
24/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Transgene : A dense clinical calendar in the coming weeks

>Financial visibility out to Q4 2025 confirmed - Transgène yesterday evening reported its H1 2024 results which contained no major surprises. Operating income totalled € 3.4m (vs € 4.8m in H1 2023). R&D costs were stable at € 15.4m and the net loss was € 16.5m (vs -€ 15.9m in H1 2023).Transgene's cash position reached € 15.3m, resulting in as expected financial visibility out to Q4 2025. This financial visibility is made possible by the fact that Transgene has al...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Transgene : Un calendrier clinique chargé dans ces prochaines semaines

>Visibilité financière jusqu’au T4 2025 confirmée - Transgène publiait hier soir ses résultats financiers du S1 2024 qui se révèlent sans grande surprise. Les produits d’exploitations atteignent 3.4 M€ (vs 4.8 M€ au S1 2023). Les coûts de R&D sont stables à 15.4 M€ et la perte nette ressort à 16.5 M€ (vs -15.9 M€ au S1 2023).La position de trésorerie de Transgène atteint 15.3 M€ conduisant à avoir comme attendu une visibilité financière jusqu’au T4 2025. Cette vi...

 PRESS RELEASE

Transgene to Report Major Clinical Data before the end of 2024 – Confi...

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025 2024 Half-Year Results and Business Update Lead program TG4050 (individualized immunotherapy): – First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median 24-month follow-up data to be presented in Q4 2024 BT-001 (oncolytic virus): Data presented at ESMO (Sept. 2024) showed promising antitumor activity in solid tu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch